How to Validate Contactless Vitals Accuracy for Regulators

The transition from traditional fluid based medical underwriting to digital decision engines has fundamentally altered how life and health insurance carriers assess risk. As carriers increasingly rely on smartphone cameras to capture biological signals, departments of insurance are intensifying their scrutiny of the underlying data. For reinsurance medical directors and chief medical officers, deploying these tools requires more than a basic software integration. It demands rigorous contactless vitals accuracy validation to prove that algorithm derived health metrics match clinical reality. When a life insurance decision rests on a 60 second video scan, regulators expect a paper trail of clinical evidence that meets the standards of traditional paramedical exams.

"To support regulatory decision making, digital health technologies that capture biometric data must demonstrate robust clinical validation against standard of care medical devices across diverse and representative subject populations." U.S. Food and Drug Administration, Framework for Digital Health Technologies, 2023

The mechanics of contactless vitals accuracy validation

Regulators evaluating remote photoplethysmography (rPPG) technologies, the core science behind smartphone based vitals, expect an empirical baseline. Thorough digital health screening validation is not a single test but a continuous framework measuring algorithmic outputs against established ground truth devices. For heart rate, this means proving equivalence to a 12 lead electrocardiogram (ECG). For respiratory rate, it requires parity with capnography or chest impedance bands.

Remote photoplethysmography operates on the principle that the human cardiovascular system causes minute changes in skin color with every heartbeat. As blood volumes fluctuate, the absorption and reflection of ambient light change accordingly. Standard RGB smartphone cameras can capture these micro fluctuations at high frame rates, allowing algorithms to extract a pulse wave. While the physics are well established, translating raw pixel data into a medical grade vital sign requires extensive algorithmic filtering. Regulators need absolute certainty that the software is isolating actual hemodynamic signals rather than tracking superficial facial movements or rhythmic background noise.

Overcoming environmental variables in remote screening

When an applicant schedules a paramedical exam, the environment is controlled by the visiting nurse. When an applicant uses a smartphone for a digital health screening, the environment is entirely uncontrolled. This lack of standardization is the primary reason regulatory bodies demand extensive environmental validation data.

Regulators look for validation testing that explicitly addresses these factors:

• Motion artifacts and micro movements during the scanning period, requiring algorithms to compensate for swallowing or head tilts.
• Variations in ambient lighting, ranging from low light conditions to harsh backlighting that could obscure the biological signal.
• Camera hardware discrepancies across different smartphone manufacturers and older operating systems.
• Performance consistency across the full Fitzpatrick skin type scale to ensure demographic fairness.

Demographic fairness and the fitzpatrick scale

A critical pillar of validating these tools is proving demographic equity. Insurance regulators, guided by frameworks from the National Association of Insurance Commissioners (NAIC) and state specific mandates, are highly focused on algorithmic discrimination. Because rPPG relies on capturing light that reflects off the skin and is absorbed by hemoglobin, melanin acts as a natural light filter. Poorly trained machine learning models often struggle to extract accurate pulse signals from individuals with higher melanin concentrations.

To satisfy underwriting technology standards, carriers must provide validation studies demonstrating equal performance across the entire Fitzpatrick skin type scale, from Type I to Type VI. If a digital vitals tool shows a statistically significant increase in error rates for darker skin tones, utilizing that tool for adverse underwriting decisions constitutes algorithmic discrimination.

Regulatory evidence tiers for underwriting

When building a compliance narrative for state insurance commissioners, clinical validation evidence typically falls into distinct tiers based on the impact of the data.

Evidence Tier	Measurement Method	Regulatory Status	Ground Truth Equivalence	Underwriting Application
Clinical Grade	Algorithmic rPPG with empirical validation	FDA 510(k) Class II Medical Device equivalent	ECG, Capnography	Automated accelerated underwriting
Consumer Grade	Standard wellness tracking applications	Unregulated general wellness tools	Optical wrist sensors	Behavioral nudges, wellness incentives
Self Reported	Applicant health questionnaires	Unregulated	Retrospective medical records	Traditional fully underwritten policies

Industry applications in modern underwriting

The requirement for strict validation protocols scales with the impact of the automated decision. State departments of insurance are drawing clear lines between data used for wellness engagement and data used for adverse action.

Primary life insurance decisioning

In primary life insurance decisioning, the stakes for data accuracy are exceptionally high. A carrier utilizing contactless vitals for straight through processing must satisfy departments of insurance that the data cannot unfairly disadvantage an applicant due to technical errors. If an applicant is routed to a higher premium tier, or denied an accelerated path entirely, based on an elevated resting heart rate detected via a smartphone, the carrier must be able to produce the clinical validation insurance documents that justify the algorithm accuracy at that specific measurement threshold.

Furthermore, state laws regarding adverse action notices require insurers to explain precisely why a rate class changed. If the carrier relies on unvalidated biometric algorithms, defending that adverse action in a regulatory audit becomes legally indefensible. Without concrete proof of algorithmic equivalence to traditional medical devices, carriers risk regulatory fines and forced model rollbacks.

Reinsurance risk modeling

Reinsurers aggregate risk across millions of policies, relying heavily on predictable mortality and morbidity curves. When treaty partners adopt new digital screening tools to replace traditional blood draws and paramedical exams, reinsurance medical directors must audit the algorithmic accuracy to ensure these mortality assumptions remain sound.

A systemic overestimation or underestimation of cardiovascular risk parameters due to poor rPPG validation can destabilize actuarial models over a 10 year or 20 year horizon. For example, if an unvalidated contactless vitals tool consistently reads heart rates five beats per minute lower than reality, the carrier will underprice the risk for a massive cohort of applicants. To prevent this, reinsurers are now mandating access to third party clinical trial data and detailed accuracy reports before approving the use of contactless technologies in carrier underwriting guidelines.

Current research and evidence

The clinical evidence base for rPPG technology has expanded significantly over the past five years, moving from theoretical computer science applications to widespread regulatory acceptance. Multiple clinical studies registered with standard clinical trial databases are actively evaluating the accuracy of rPPG for measuring pulse rate, respiratory rate, and oxygen saturation in patients with diagnosed cardiovascular diseases.

A 2024 study led by researchers Jing Wei Chin, Po Him David Chan, and colleagues at the Chinese University of Hong Kong provided substantial regulatory filing evidence for the industry. The research team evaluated rPPG enabled contactless pulse rate monitoring software specifically in patients with cardiovascular disease. This distinction is critical because algorithms trained exclusively on healthy, resting individuals often fail when presented with arrhythmias, atrial fibrillation, or generally abnormal cardiac outputs. By collecting rPPG data via standard cameras and simultaneously recording vital signs using standard of care bedside monitors, the researchers demonstrated strong agreement with ECG derived pulse rates, proving that the technology holds up even when evaluating medically complex applicants.

In 2023 and 2024, regulatory agencies established clear precedents by granting FDA clearances for several software as a medical device platforms that utilize rPPG for heart rate and respiratory rate measurement. These clearances signal to insurance regulators that when properly validated, contactless extraction of biological signals meets the strict safety and efficacy thresholds required for clinical decision making.

The future of contactless vitals validation

As automated underwriting frameworks mature, the expectations for validation will expand beyond basic vital signs to encompass more complex hemodynamic parameters. Researchers are currently conducting multi center trials to validate AI based facial scans for multimodal health assessments, including blood pressure trending and atrial fibrillation detection.

Regulators are also signaling a shift toward continuous post market surveillance. Instead of a one time validation study, compliance frameworks will likely require carriers to submit annual accuracy audits. This ensures that as algorithms are updated or retrained on new datasets, they do not experience model drift that could compromise their clinical accuracy or introduce new biases into the underwriting pool.

Frequently asked questions

What is the standard reference device for validating contactless heart rate? The standard ground truth reference for validating algorithmic or contactless heart rate measurements is a 12 lead Electrocardiogram (ECG). Because an ECG directly measures the electrical activity of the heart, it provides the most accurate baseline for comparing the optically derived pulse waves generated by remote photoplethysmography algorithms.

Do state insurance regulators require FDA clearance for underwriting tools? While not strictly required for non diagnostic insurance underwriting in all jurisdictions, an FDA 510(k) clearance or equivalent clinical validation standard is increasingly treated by state regulators as the benchmark for algorithmic safety and accuracy. Departments of insurance view clinical grade validation as a strong defense against claims of unfair discrimination.

How does skin tone affect contactless vitals validation? Because rPPG relies on light absorption and reflection to detect blood volume changes, poorly trained algorithms can struggle with darker skin tones, where melanin acts as a natural light filter. Regulators require rigorous validation across all six categories of the Fitzpatrick skin type scale to prove demographic fairness and ensure the tool works equally well for all applicants.

What statistical methods are used to prove measurement accuracy? Researchers and data scientists typically use Bland Altman analysis to evaluate the agreement between the contactless technology and the clinical reference device. Regulatory submissions focus heavily on the mean bias, the upper and lower limits of agreement, and the root mean square error (RMSE) to prove that the algorithmic variance falls within acceptable medical margins.

Navigating the complex requirements of modern insurance regulation requires a proactive approach to clinical and algorithmic evidence. Circadify is actively addressing this space by providing comprehensive resources for underwriting compliance and automated health assessments. Reinsurance medical directors and carrier compliance teams can review our full validation evidence package and compliance guides at circadify.com/industries/payers-insurance.